Caption Management’s UroGen Pharma URGN Stock Holding History

Caption Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-70,000	Closed	-$1.4M	–	2081
2025 Q3	$1.4M	Buy	+70,000	New	+$1.26M	0.01%	988
2024 Q3	–	Sell	-68,000	Closed	-$1.14M	–	1595
2024 Q2	$1.14M	Buy	+68,000	New	+$967K	0.02%	630
2023 Q3	–	Sell	-2,400	Closed	-$24.8K	–	1560
2023 Q2	$24.8K	Buy	+2,400	New	+$26.5K	﹤0.01%	1026

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Caption Management's URGN Position: Q2 2026 in Review

Caption Management sold out of UroGen Pharma (URGN) in Q2 2026, closing a stake of 4,124 shares — an estimated $74.2K sold.

Caption Management first reported a position in URGN in Q1 2026 and held it in 1 quarter. The position peaked at $74.2K in Q1 2026. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Caption Management reported no remaining UroGen Pharma position as of Q2 2026 after selling out during the quarter.
Caption Management sold 4,124 UroGen Pharma shares in Q2 2026, an estimated $74.2K.
Caption Management first reported a position in UroGen Pharma in Q1 2026 and held it in 1 quarter.
Caption Management's UroGen Pharma position peaked at $74.2K in Q1 2026.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.